Fig. 3

Prevalence of patients meeting the criteria for metabolic syndrome in tirzepatide-treated patients by weight loss category (< 15% or ≥ 15%). Data are proportion of tirzepatide-treated patients with at least 3 diagnostic criteria for metabolic syndrome at the primary endpoint of 40/52 weeks by weight loss category (< 15% or ≥ 15%). MET: metformin; SGLT2i: sodium-glucose co-transporter 2 inhibitor; SU: sulfonylurea